Literature DB >> 6294139

Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

W M Canfield, W Kisiel.   

Abstract

Human activated protein C (APC) is a plasma serine protease that possesses amidolytic and anticoagulant activity. The rate at which the amidolytic and anticoagulant activity of APC was neutralized in normal plasma was essentially identical to that observed in plasma obtained from four individuals with combined Factor V/VIII deficiency disease. Incubation of radioiodinated APC with either normal human plasma or the combined Factor V/VIII-deficient plasmas resulted in the formation of a stable complex (Mr = 96,000) of the enzyme and a plasma protein as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Pretreatment of the radiolabeled APC with diisopropyl fluorophosphate prevented the formation of the enzyme-protein complex. On the basis of its ability to form a complex with radiolabeled APC, the APC-binding protein was purified to homogeneity from normal human plasma by ammonium sulfate fractionation, heparin-agarose chromatography, and QAE-Sephadex A-50 chromatography. The APC-binding protein (Mr = 54,000) is a glycoprotein, and possesses an amino-terminal sequence of Gly-Arg-Thr-Cys-Pro-Lys-Pro-Asp. The amino-terminal sequence of the APC-binding protein exhibited considerable homology with bovine colostrum inhibitor and pancreatic trypsin inhibitor, but no apparent sequence homology with the plasma serine protease inhibitors. Affinity-purified antibody against APC-binding protein immunoprecipitated a complex of radiolabeled APC and native APC-binding protein from normal human plasma. Complex formation was virtually eliminated in plasma immunodepleted of the APC-binding protein. Quantitative electroimmunoassay indicated essentially equal levels of APC-binding protein antigen in normal plasma compared with plasma from four patients with combined Factor V/VIII deficiency disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6294139      PMCID: PMC370343          DOI: 10.1172/jci110725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Isolation and characterization of bovine factor VII.

Authors:  W Kisiel; E W Davie
Journal:  Biochemistry       Date:  1975-11-04       Impact factor: 3.162

2.  A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization.

Authors:  J Stenflo
Journal:  J Biol Chem       Date:  1976-01-25       Impact factor: 5.157

3.  N-terminal amino acid sequences of variant-specific surface antigens from Trypanosoma brucei.

Authors:  P J Bridgen; G A Cross; J Bridgen
Journal:  Nature       Date:  1976-10-14       Impact factor: 49.962

4.  Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates.

Authors:  T E Hugli; S Moore
Journal:  J Biol Chem       Date:  1972-05-10       Impact factor: 5.157

5.  Carbamylated human immunoglobulins tested by electrophoresis in agarose and antibody containing agarose.

Authors:  B Weeke
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

6.  Crossed immunoelectrophoresis.

Authors:  P O Ganrot
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  The chromatographic determination of cystine and cysteine residues in proteins as s-beta-(4-pyridylethyl)cysteine.

Authors:  M Friedman; L H Krull; J F Cavins
Journal:  J Biol Chem       Date:  1970-08-10       Impact factor: 5.157

9.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

10.  A protein sequenator.

Authors:  P Edman; G Begg
Journal:  Eur J Biochem       Date:  1967-03
View more
  18 in total

1.  Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping.

Authors:  W C Nichols; U Seligsohn; A Zivelin; V H Terry; N D Arnold; D R Siemieniak; R J Kaufman; D Ginsburg
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  The locus for combined factor V-factor VIII deficiency (F5F8D) maps to 18q21, between D18S849 and D18S1103.

Authors:  M Neerman-Arbez; S E Antonarakis; J L Blouin; S Zeinali; M Akhtari; Y Afshar; E G Tuddenham
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

3.  Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.

Authors:  W H Kane; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  The alpha and beta chains of human platelet glycoprotein Ib are both transmembrane proteins containing a leucine-rich amino acid sequence.

Authors:  J A Lopez; D W Chung; K Fujikawa; F S Hagen; E W Davie; G J Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

Review 5.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

6.  Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.

Authors:  G M Rodgers; W H Kane
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Cloning and characterization of two cDNAs coding for human von Willebrand factor.

Authors:  J E Sadler; B B Shelton-Inloes; J M Sorace; J M Harlan; K Titani; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Complete amino acid sequence of human plasma beta 2-glycoprotein I.

Authors:  J Lozier; N Takahashi; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Characterization of a cDNA coding for human factor X.

Authors:  S P Leytus; D W Chung; W Kisiel; K Kurachi; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.